KNOPMAN, David S.; AMIEVA, Helene; PETERSEN, Ronald C.; CHETELAT, Gael; HOLTZMAN, David M.; HYMAN, Bradley T.; NIXON, Ralph A.; JONES, David T.

doi:10.1038/s41572-021-00269-y

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

KNOPMAN, David S.

AMIEVA, Helene

Bordeaux population health [BPH]

PETERSEN, Ronald C.

Idioma

Article de revue

Este ítem está publicado en

Nature reviews Disease primers. 2021-05-13, vol. 7, n° 1, p. 33

Resumen en inglés

Alzheimer disease (AD) is biologically defined by the presence of beta-amyloid-containing plaques and tau-containing neurofibrillary tangles. AD is a genetic and sporadic neurodegenerative disease that causes an amnestic cognitive impairment in its prototypical presentation and non-amnestic cognitive impairment in its less common variants. AD is a common cause of cognitive impairment acquired in midlife and late-life but its clinical impact is modified by other neurodegenerative and cerebrovascular conditions. This Primer conceives of AD biology as the brain disorder that results from a complex interplay of loss of synaptic homeostasis and dysfunction in the highly interrelated endosomal/lysosomal clearance pathways in which the precursors, aggregated species and post-translationally modified products of Abeta and tau play important roles. Therapeutic endeavours are still struggling to find targets within this framework that substantially change the clinical course in persons with AD.< Leer menos

Palabras clave en inglés

Alzheimer's disease

Diagnostic markers

Translational research

Metadatos

Compartir este ítem

Licencia de uso del documento

Alzheimer disease

Idioma

Este ítem está publicado en

Resumen en inglés

Palabras clave en inglés

URI

DOI

Centros de investigación